Utility of Survival Motor Neuron ELISA for Spinal Muscular Atrophy Clinical and Preclinical Analyses

@inproceedings{Kobayashi2011UtilityOS,
  title={Utility of Survival Motor Neuron ELISA for Spinal Muscular Atrophy Clinical and Preclinical Analyses},
  author={Dione T. Kobayashi and Rory J. Olson and Laurel Sly and Chad J. Swanson and Brett Chung and Nikolai N Naryshkin and Jana Narasimhan and Anuradha Bhattacharyya and Michael C. Mullenix and Karen S. Chen},
  booktitle={PloS one},
  year={2011}
}
OBJECTIVES Genetic defects leading to the reduction of the survival motor neuron protein (SMN) are a causal factor for Spinal Muscular Atrophy (SMA). While there are a number of therapies under evaluation as potential treatments for SMA, there is a critical lack of a biomarker method for assessing efficacy of therapeutic interventions, particularly those targeting upregulation of SMN protein levels. Towards this end we have engaged in developing an immunoassay capable of accurately measuring… CONTINUE READING